APExBIO - CBL0137 (hydrochloride) | curaxin that activates p53 and inhibits NF-κB | CAS# 1197397-89-9
CBL0137 preferentially kills GSCs over NSTCs by targeting FACT. A, GSCs... | Download Scientific Diagram
CBL0137 overcomes developmental signals that drive neuroblast... | Download Scientific Diagram
New Strategy For Stubborn Neuroblastomas
CBL0137 | ≥99%(HPLC) | Selleck | NF-κB inhibitor
Frontiers | The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression | Oncology
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG
Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy | SpringerLink
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Pr
Acute exposure to CBL0137 decreases CD133 cell-surface expression and... | Download Scientific Diagram
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma
FACT Complex-targeting Curaxin CBL0137 for Refractory Lymphomas Clinical Trial | Power
The small molecule drug CBL0137 increases the level of DNA damage and the efficacy of radiotherapy for glioblastoma - ScienceDirect
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
Potent antileukemic activity of curaxin CBL0137 against MLL‐rearranged leukemia - Somers - 2020 - International Journal of Cancer - Wiley Online Library
Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137 | Cell Death & Disease
CBL0137 hydrochloride (Curaxin-137 hydrochloride) | MDM-2/p53 p53 Activator | MedChemExpress
Stimulation of an anti-tumor immune response with “chromatin-damaging” therapy | SpringerLink
CBL0137 HCl | ≥99%(HPLC) | Selleck | p53 activator
IJMS | Free Full-Text | Exploring the Interaction of Curaxin CBL0137 with G-Quadruplex DNA Oligomers | HTML
Anticancer Drug Cbl0137 Highly Effective Against Infant Leukaemia | CCI
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pan
